Piramal Pharma Limited (NSE:PPLPHARMA)
India · Delayed Price · Currency is INR 190.65
-6.38 (-3.24%)
Aug 1, 2025, 3:30 PM IST
Verve Therapeutics Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 91,338 | 91,512 | 81,712 | 70,816 | 65,591 | 58,291 |
Other Revenue | - | - | - | - | 1,750 | 576.37 |
| 91,338 | 91,512 | 81,712 | 70,816 | 67,341 | 58,868 | |
Revenue Growth (YoY) | 9.08% | 11.99% | 15.39% | 5.16% | 14.39% | - |
Cost of Revenue | 35,748 | 35,551 | 32,617 | 29,713 | 24,512 | 20,736 |
Gross Profit | 55,590 | 55,961 | 49,095 | 41,103 | 42,829 | 38,132 |
Selling, General & Admin | 25,560 | 25,171 | 22,034 | 21,046 | 15,888 | 14,761 |
Other Operating Expenses | 16,517 | 16,299 | 15,054 | 13,736 | 15,477 | 9,508 |
Operating Expenses | 50,367 | 49,633 | 44,493 | 41,549 | 37,227 | 29,301 |
Operating Income | 5,223 | 6,328 | 4,601 | -446.5 | 5,602 | 8,831 |
Interest Expense | -3,971 | -4,179 | -4,470 | -3,377 | -1,888 | -1,459 |
Interest & Investment Income | 105.8 | 105.8 | 119.2 | 16.4 | 6.8 | 37.11 |
Earnings From Equity Investments | 691 | 729.3 | 594.9 | 543.3 | 590.3 | 436.06 |
Currency Exchange Gain (Loss) | 380.9 | 380.9 | 304 | 1,108 | 168.6 | 565.57 |
Other Non Operating Income (Expenses) | 883.1 | 494.5 | 762.6 | 523.3 | -94.7 | -50.12 |
EBT Excluding Unusual Items | 3,312 | 3,859 | 1,912 | -1,633 | 4,385 | 8,361 |
Merger & Restructuring Charges | - | - | - | -69.6 | -150.8 | -416.77 |
Gain (Loss) on Sale of Investments | 90.5 | 90.5 | 43.5 | 15.8 | 19.5 | - |
Gain (Loss) on Sale of Assets | 14.4 | 14.4 | -4.6 | -4.8 | -5.4 | 10.52 |
Asset Writedown | - | - | - | - | - | -377.08 |
Other Unusual Items | 390 | 182.6 | -158.4 | 490 | 601.3 | 1,183 |
Pretax Income | 3,807 | 4,146 | 1,793 | -1,202 | 4,850 | 8,760 |
Income Tax Expense | 2,826 | 3,235 | 1,615 | 663.1 | 1,090 | 1,052 |
Net Income | 980.7 | 911.3 | 178.2 | -1,865 | 3,760 | 7,708 |
Net Income to Common | 980.7 | 911.3 | 178.2 | -1,865 | 3,760 | 7,708 |
Net Income Growth | 253.28% | 411.39% | - | - | -51.23% | - |
Shares Outstanding (Basic) | 1,322 | 1,323 | 1,281 | 1,190 | 1,179 | 628 |
Shares Outstanding (Diluted) | 1,329 | 1,331 | 1,284 | 1,190 | 1,179 | 628 |
Shares Change (YoY) | 1.48% | 3.67% | 7.85% | 0.95% | 87.83% | - |
EPS (Basic) | 0.74 | 0.69 | 0.14 | -1.57 | 3.19 | 12.28 |
EPS (Diluted) | 0.73 | 0.68 | 0.14 | -1.57 | 3.19 | 12.28 |
EPS Growth | 245.21% | 388.86% | - | - | -74.02% | - |
Free Cash Flow | - | 2,279 | 2,925 | -4,809 | -1,231 | -42.55 |
Free Cash Flow Per Share | - | 1.71 | 2.28 | -4.04 | -1.04 | -0.07 |
Dividend Per Share | - | 0.140 | 0.110 | - | 0.980 | - |
Dividend Growth | - | 27.27% | - | - | - | - |
Gross Margin | 60.86% | 61.15% | 60.08% | 58.04% | 63.60% | 64.78% |
Operating Margin | 5.72% | 6.92% | 5.63% | -0.63% | 8.32% | 15.00% |
Profit Margin | 1.07% | 1.00% | 0.22% | -2.63% | 5.58% | 13.09% |
Free Cash Flow Margin | - | 2.49% | 3.58% | -6.79% | -1.83% | -0.07% |
EBITDA | 12,759 | 13,715 | 11,391 | 5,764 | 11,099 | 12,970 |
EBITDA Margin | 13.97% | 14.99% | 13.94% | 8.14% | 16.48% | 22.03% |
D&A For EBITDA | 7,537 | 7,387 | 6,790 | 6,211 | 5,497 | 4,139 |
EBIT | 5,223 | 6,328 | 4,601 | -446.5 | 5,602 | 8,831 |
EBIT Margin | 5.72% | 6.92% | 5.63% | -0.63% | 8.32% | 15.00% |
Effective Tax Rate | 74.24% | 78.02% | 90.06% | - | 22.48% | 12.01% |
Revenue as Reported | 93,074 | 92,860 | 83,466 | 73,067 | 68,349 | 59,806 |
Advertising Expenses | - | 1,767 | 1,423 | 1,762 | 1,513 | - |
Updated Jan 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.